Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KRX-0502 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| KRX-0502 | EXPERIMENTAL | KRX-0502 (ferric citrate) |
| Name | Type | Description |
|---|---|---|
| KRX-0502 | DRUG | 1g tablets of KRX-0502 |
Inclusion Criteria: * Males and non-lactating females with negative serum pregnancy test (for females of child-bearing potential) at Screening * Age ≥ 18 years * Serum ferritin ≤ 300 ng/mL and TSAT ≤ 25% at Screening * Hemoglobin ≥9.0 g/dL and ≤11.5 g/dL at Screening * eGFR \<60 mL/min at Screening...
KRX-0502 is an investigational small molecule being studied for the treatment of anemia of chronic kidney disease. It is being developed by Akebia Therapeutics, Inc. (NASDAQ: AKBA). The drug is currently in Phase 2 clinical development, and it has not been approved by the FDA.
KRX-0502 is being developed by Akebia Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol AKBA. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with anemia of chronic kidney disease.
KRX-0502 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of anemia of chronic kidney disease, and its clinical trial program is ongoing.
KRX-0502 has one completed Phase 2 clinical trial registered as NCT02128074. This pilot study evaluated the drug in 32 patients with anemia of chronic kidney disease in Israel. The trial was not randomized or double-blinded and did not use a control group.
KRX-0502 is also known as ferric citrate. In clinical trials, it is being studied for the treatment of iron-deficiency anemia in patients with chronic kidney disease. The drug is administered without food, as specified in the Phase 2 study protocol.